CN106309535A - Compound medicine containing triquetrous tadehagi herbs and fosfomycin and used for livestock - Google Patents
Compound medicine containing triquetrous tadehagi herbs and fosfomycin and used for livestock Download PDFInfo
- Publication number
- CN106309535A CN106309535A CN201610753839.1A CN201610753839A CN106309535A CN 106309535 A CN106309535 A CN 106309535A CN 201610753839 A CN201610753839 A CN 201610753839A CN 106309535 A CN106309535 A CN 106309535A
- Authority
- CN
- China
- Prior art keywords
- fosfomycin
- triquetri
- herba
- compound medicine
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a compound medicine containing triquetrous tadehagi herbs and fosfomycin and used for livestock. The compound medicine is prepared from raw materials in parts by weight as follows: 3-30 parts of the fosfomycin and 10-170 parts of the triquetrous tadehagi herbs. The compound medicine for the livestock is prepared from the traditional Chinese medicine material, namely, the triquetrous tadehagi herbs, and the fosfomycin, the fosfomycin is an antibacterial drug, and after the antibacterial drug is added to the triquetrous tadehagi herbs, the drug resistance of bacteria to the antibacterial drug can be inverted, so that the treatment effect of the antibacterial drug is improved; further, the medicine cost and medicine residues of the compound medicine can be substantially reduced, higher economic benefits are created for farmers, and besides, the food safety is also ensured.
Description
Technical field
The invention belongs to poultry coli-infection treatment technology field, be specifically related to a kind of containing Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and fosfomycin
Poultry compound medicine.
Background technology
Escherichia coli are common conditioned pathogens, are also a kind of diseases often sent out, and it primary can cause the acute deteriorated blood of chicken
The multiple location severe infections such as disease, peritonitis, hepatitis, pneumonia, enteritis, also can secondary or mixed send out in virosis, cause to aquaculture
Huge economic loss.Amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, ammonia benzyl west
The beta-lactam nucleus class antibiotic such as woods/sulbactam are the conventional important drugs preventing and treating this disease.Along with the cultivation intensive journey of scale
Degree is more and more big, and medication is more and more spread unchecked, and its Resistant strain is the most, and the report about Drug Resistance of E. coli is the most more.
Research confirms, one of main mechanism of drug resistance is to produce beta-lactamase, especially extended spectrumβ-lactamase (Extended-
Spectrum β-lactamase, ESBLs), this enzyme can hydrolyze beta-lactam nucleus more by force and rapidly, makes this kind of antibiotic lose
Antibacterial activity.ESBLs is the main enzyme type of beta-lactamase, and it is not only to cephalo three generations and aztreonam drug resistance, and to ammonia
Base glucosides class, quinolones and sulfonamides are crossing drug resistant, only to carbapenems, a mould alkenes medicaments insensitive.Many documents
It has been reported that colibacillary multi-drug resistant with produce ESBLs have substantial connection, both at home and abroad to more pay close attention to.Inventor is
The detection of food animal source pathogenic bacterium ESBLs, extraction, enzyme are closely carried out to the percent hydrolysis of antibiotic and sulbactam, Tazobactam Sodium
And the research such as the enzyme protection effect that presses down of Chinese medicine, drug sensitive test colibacillary to part ESBLs shows, its multidrug resistant rate is bright
Aobvious higher than non-ESBLs bacterial strain.It addition, result also shows that product ESBLs bacterial strain is not only tight to third generation cephalosporins such as ceftiofurs
Weight drug resistance, and also antimicrobial drug drug resistance multiple to fluoroquinolones, aminoglycoside and sulfonamides, fosfomycin etc., in serious
Multidrug resistant.Inventor is separated to resistance to fosfomycin in producing ESBLs bacterial strain and produces the escherichia coli of fosA3 drug resistant gene, more strengthens
The drug resistance of antibacterial.
Colibacillary drug resistance causes raiser's drug cost to increase, and treatment extends the course for the treatment of, and mortality of livestock increases, and gives
Production brings bigger economic loss, and increases poultry drug residue risk.Therefore, actual production is needed one to either badly
The escherichia coli of no drug resistance can have a medicine of preferable therapeutical effect, and can shorten treatment course for the treatment of, reduces mortality rate, reduces economy
Loss and reduction drug residue, create higher economic benefit for raiser, also ensure that the mankind's is healthy and safe.
The information being disclosed in this background section is merely intended to increase the understanding of the general background to the present invention, and should not
When being considered to recognize or imply in any form this information structure prior art well known to persons skilled in the art.
Summary of the invention
The present invention solves above-mentioned technical problem, it is provided that a kind of poultry compound medicine containing Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and fosfomycin,
It can kill antibacterial quickly, overcomes weak curative effect, the consumption caused due to drug resistance problems in antimicrobial drug therapeutic process big, residual
Stay high and that cost is high defect, it is to avoid simple Chinese medicine sterilizing spectrum is narrow, sterilize slow problem.
For achieving the above object, the technical scheme that the present invention provides is as follows:
A kind of poultry compound medicine containing Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and fosfomycin, is made up of following raw material according to ratio of weight and number:
Fosfomycin 3-30 part and Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 10-170 part.
Wherein, described Herba Desmodii Triquetri (Herba Tadehagi Triquetri) is for pulverizing and sieving rear gained.
Wherein, described Herba Desmodii Triquetri (Herba Tadehagi Triquetri) crosses 60 mesh sieves after pulverizing.
Wherein, the preparation method of described compound medicine is: by ratio of weight and the number of copies, takes the Herba Desmodii Triquetri (Herba Tadehagi Triquetri) after pulverizing and powder
Fosfomycin, Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and fosfomycin are mixed, are prepared as required dosage form according to a conventional method, to obtain final product.
Wherein, described dosage form is the one in powder, tablet, oral liquid or granule.
Wherein, after above-mentioned compound medicine makes powder, tablet, oral liquid or granule dosage form, add according to every 1kg feedstuff
The addition of 0.1-7g resulting dosage forms adds in animal and fowl fodder and feeds.
Wherein, the poultry containing Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and fosfomycin as mentioned above are used for treating poultry by escherichia coli with compound medicine
The disease caused.
Compared with prior art, there is advantages that
Poultry compound medicine of the present invention, utilizes Chinese medicine Herba Desmodii Triquetri (Herba Tadehagi Triquetri) to form compound medicine with fosfomycin, and fosfomycin is antibacterial
After medicine, i.e. antimicrobial drug add Herba Desmodii Triquetri (Herba Tadehagi Triquetri), it is possible to the reverse bacterial drug resistance to antimicrobial drug, thus improve the treatment effect of antimicrobial drug
Really；Further product of the present invention can be greatly reduced drug cost and drug residue, creates higher economic benefit for raiser,
Also ensure that food safety simultaneously.
Detailed description of the invention
It is described in detail below in conjunction with detailed description of the invention, it is to be understood that protection scope of the present invention is not by concrete
The restriction of embodiment.
One, the Herba Desmodii Triquetri (Herba Tadehagi Triquetri) drug resistance inversion Effect study to fosfomycin
Fosfomycin is antimicrobial drug, itself has the colibacillary effect for the treatment of, but owing to producing the large intestine bar of drug resistant gene
Bacterium has stronger drug resistance, causes antimicrobial drug not show preferable therapeutic effect in the case of normal using dosage.
1, to colibacillary drug resistance inhibition test after Herba Desmodii Triquetri (Herba Tadehagi Triquetri) mixes with fosfomycin
96 orifice plates use microtest tube doubling dilution, first determines fosfomycin to producing ESBLs and fosA3 drug resistance base
The Asia producing ESBLs and fosA3 drug resistant gene e. coli strains is pressed down by minimal inhibitory concentration and the Herba Desmodii Triquetri (Herba Tadehagi Triquetri) of the e. coli strains of cause
Bacteria concentration, the Herba Desmodii Triquetri (Herba Tadehagi Triquetri) adding subinhibitory concentration the most in the medium reuses microtest tube doubling dilution cultivation mensuration
The minimal inhibitory concentration of fosfomycin；Utilize continuous passage method added with same subinhibitory concentration Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and same phosphorus concentration mycin
Culture medium in carry out Secondary Culture, until the fosfomycin observed is to producing ESBLs and fosA3 drug resistant gene e. coli strains
Little Mlc with pass on before compared with diminish more than 4 times, can be judged as that Herba Desmodii Triquetri (Herba Tadehagi Triquetri) has drug resistance inversion effect to fosfomycin, examination
Test result statistics as shown in table 1:
Table 1 subinhibitory concentration (0.125g/mL) Herba Desmodii Triquetri (Herba Tadehagi Triquetri) passes on to cause and produces ESBLs and fosA3 escherichia coli Western medicine MIC's
Change (μ g/mL).
As shown in Table 1, fosfomycin all reduces more than 4 times to the minimal inhibitory concentration of antibiotic-resistance E. coli, i.e. can determine whether be
Herba Desmodii Triquetri (Herba Tadehagi Triquetri) has drug resistance inversion effect to producing ESBLs and fosA3 drug resistant gene escherichia coli.
Two, the example of compound medicine of the present invention
Embodiment 1
Herba Desmodii Triquetri (Herba Tadehagi Triquetri) was pulverized 60 mesh sieves, standby；In units of g, weigh Herba Desmodii Triquetri (Herba Tadehagi Triquetri) standby after 18g pulverizes, 130g powder
Powder fosfomycin, then will weigh gained Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and fosfomycin is put in blender and mixed, conventionally, after mixing
Gained makes powder processed, obtains product.Prepare products obtained therefrom for treating the disease that poultry are caused by escherichia coli.
Embodiment 2
The method repeating embodiment 1 by each component specified in table 2 below and each parameter content, makes tablet, obtains product
Product.
Embodiment 3
The method repeating embodiment 1 by each component specified in table 2 below and each parameter content, makes oral liquid, to obtain final product
Product.
Embodiment 4
The method repeating embodiment 1 by each component specified in table 2 below and each parameter content, makes granule, to obtain final product
Product.
The formula of table 2 embodiment 1-4 and preparation dosage form
| Numbering | Antimicrobial drug | Herba Desmodii Triquetri (Herba Tadehagi Triquetri) | Dosage form |
| Embodiment 1 | Fosfomycin 18g | 130g | Powder |
| Embodiment 2 | Fosfomycin 3g | 50g | Tablet |
| Embodiment 3 | Fosfomycin 9g | 10g | Oral liquid |
| Embodiment 4 | Fosfomycin 30g | 170g | Granule |
Three, above-described embodiment is obtained compound medicine product and has carried out following experiment:
1, the meat-type duck of duck field 30, Liuzhou age in days is suffered from diarrhoea and is carried out curative effect by the compound medicine product of above-described embodiment 1-4 gained
Experiment.
Clinical symptoms: duck group draws watery stools, has obvious indigested feedstuff in feces.The serious duck of indivedual diarrhoea by
Appearance foot gradually is soft slowly dead.
Cuing open inspection pathological changes: the duck that dies of illness dehydration ratio is more serious, indivedual ducks are the biggest, duck liver enlargement, hyperemia, the liver of part duck
Having white films on dirty, air bag is muddy, and tentative diagnosis is escherichia coli or duck oromeningitis.
Test therapeutic regimen: morbidity duck group divides six groups of administrations, first group by embodiment 1 according to the interpolation of 0.8g/kg feedstuff
Amount is administered (addition that i.e. every 1kg feedstuff adds 0.8g embodiment 1 gained powder product adds animal and fowl fodder to), second group of use
Embodiment 2 is administered according to the addition of 1.8g/kg feedstuff that (i.e. every 1kg feedstuff adds adding of 1.8g embodiment 2 gained tablet
Dosage adds animal and fowl fodder to), the 3rd group is administered according to the addition of 1.8g/kg feedstuff by embodiment 3 that (i.e. every 1kg feedstuff adds
The addition adding 2g embodiment 3 gained oral liquid product adds animal and fowl fodder to), the 4th group by embodiment 4 according to 0.65g/kg
(addition that i.e. every 1kg feedstuff adds 0.65g embodiment 4 gained granule product adds poultry in the addition administration of feedstuff
Feedstuff)；5th group is administered (i.e. every 1kg feedstuff interpolation 0.1g fosfomycin with fosfomycin powder according to the addition of 0.1g/kg feedstuff
The addition of powder adds in animal and fowl fodder), the 6th group is administered according to the addition of 4g/kg feedstuff with the thick powder of Herba Desmodii Triquetri (Herba Tadehagi Triquetri)
(addition that i.e. every 1kg feedstuff adds the thick powder of 4g Herba Desmodii Triquetri (Herba Tadehagi Triquetri) adds in animal and fowl fodder)；Above six groups of therapeutic regimens are all held
Continuous use 5 days.
Using effect is fed back: after first group to the 4th group medication 3 days, and sick duck no longer draws watery stools, formed stools, no longer
Dead duck occur, be continuing with 2 days, duck group be almost recovered；After 5th group of medication 3 days, duck group's DeGrain, the most still draws water
Sample feces, containing indigested feedstuff, is continuing with 2 days, somewhat takes a turn for the better, but the best thorough, and dilute watery stools is still
Occurring, raiser uses the compound medicine of embodiment 1 gained instead, is continuing with 3 days, and feces all transfers to normally；6th group of medication 3
After it, duck does not has the biggest remarkable improvement, is continuing with 2 days, and the duck phenomena of mortality are still without being effectively controlled.Visible, contain
The compound medicine of Herba Desmodii Triquetri (Herba Tadehagi Triquetri) is far superior to folk prescription fosfomycin and folk prescription Herba Desmodii Triquetri (Herba Tadehagi Triquetri) to the curative effect that duck is suffered from diarrhoea.
The aforementioned description to the specific illustrative embodiment of the present invention illustrates that and the purpose of illustration.These describe
It is not wishing to limit the invention to disclosed precise forms, and it will be apparent that according to above-mentioned teaching, can much change
And change.The purpose selected exemplary embodiment and describe is to explain that the certain principles of the present invention and reality thereof should
With so that those skilled in the art be capable of and utilize the present invention various different exemplary and
Various different selections and change.The scope of the present invention is intended to be limited by claims and equivalents thereof.
Claims (7)
1. one kind contains Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and the poultry compound medicine of fosfomycin, it is characterised in that according to ratio of weight and number by following
Raw material forms: fosfomycin 3-30 part and Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 10-170 part.
Contain the poultry compound medicine of Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and fosfomycin the most according to claim 1, it is characterised in that: described calabash
Reed tea is for pulverizing and sieving rear gained.
Contain the poultry compound medicine of Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and fosfomycin the most according to claim 1, it is characterised in that: described calabash
Reed tea crosses 60 mesh sieves after pulverizing.
The preparation method of the poultry compound medicine containing Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and fosfomycin the most according to claim 1, its feature
It is: by ratio of weight and the number of copies, takes Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and fosfomycin, Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and fosfomycin are mixed, is prepared as required dosage form, to obtain final product.
The most according to claim 4, contain the preparation method of the poultry compound medicine of Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and fosfomycin, its feature exists
In: described dosage form is the one in powder, tablet, oral liquid or granule.
The most according to claim 4, contain the preparation method of the poultry compound medicine of Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and fosfomycin, its feature exists
In: after above-mentioned compound medicine makes powder, tablet, oral liquid or granule dosage form, add 0.1-7g gained according to every 1kg feedstuff
The addition of dosage form adds in animal and fowl fodder and feeds.
7. one kind contains Herba Desmodii Triquetri (Herba Tadehagi Triquetri) and the poultry compound medicine of fosfomycin as claimed in claim 1, it is characterised in that: this medicine
For treating the disease that poultry are caused by escherichia coli.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610753839.1A CN106309535A (en) | 2016-08-29 | 2016-08-29 | Compound medicine containing triquetrous tadehagi herbs and fosfomycin and used for livestock |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610753839.1A CN106309535A (en) | 2016-08-29 | 2016-08-29 | Compound medicine containing triquetrous tadehagi herbs and fosfomycin and used for livestock |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106309535A true CN106309535A (en) | 2017-01-11 |
Family
ID=57788352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610753839.1A Pending CN106309535A (en) | 2016-08-29 | 2016-08-29 | Compound medicine containing triquetrous tadehagi herbs and fosfomycin and used for livestock |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106309535A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103977089A (en) * | 2014-05-14 | 2014-08-13 | 广西大学 | Compound medicine containing radix paeoniae rubrathe and phosphonomycin used for livestock and poultry |
| CN103989726A (en) * | 2014-05-28 | 2014-08-20 | 广西大学 | Acalypha australis L. and fosfomycin containing compound medicine for livestock and poultry |
-
2016
- 2016-08-29 CN CN201610753839.1A patent/CN106309535A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103977089A (en) * | 2014-05-14 | 2014-08-13 | 广西大学 | Compound medicine containing radix paeoniae rubrathe and phosphonomycin used for livestock and poultry |
| CN103989726A (en) * | 2014-05-28 | 2014-08-20 | 广西大学 | Acalypha australis L. and fosfomycin containing compound medicine for livestock and poultry |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690952B (en) | The compound medicine for the treatment of poultry coli-infection disease | |
| CN103948930B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug | |
| CN103977089B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fosfomycin | |
| CN103933086A (en) | Creat/amikacin-containing compound medicine for livestock and fowl | |
| CN103948656B (en) | A kind of poultry compound medicine containing Herba Andrographis and fosfomycin | |
| CN103989729A (en) | Acalypha australis L. and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103948691B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and sulfamonomethoxine sodium | |
| CN103977088B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent | |
| CN104306420A (en) | Balsamiferou blumea herb and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103989726A (en) | Acalypha australis L. and fosfomycin containing compound medicine for livestock and poultry | |
| CN104337847B (en) | A kind of livestock and poultry compound medicine containing phoenix-tail fern and phosphonomycin | |
| CN103908670B (en) | A kind of compound treating poultry coli-infection disease | |
| CN103933544B (en) | A kind of poultry compound medicine containing Herba Andrographis and colistin | |
| CN103933543B (en) | Utilize the method for Herba Andrographis and colistin treatment poultry coli-infection disease | |
| CN104436160A (en) | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry | |
| CN103933085B (en) | The application of Herba Andrographitis and phosphonomycin in the compound medicine for preparing treatment livestock and poultry coli-infection disease | |
| CN106309535A (en) | Compound medicine containing triquetrous tadehagi herbs and fosfomycin and used for livestock | |
| CN104306422A (en) | Balsamiferou Blumea herb and beta-lactam antibacterial drug containing compound medicine for livestock and poultry | |
| CN104435040A (en) | Balsamiferou blumea herb and fosfomycin containing compound medicine for livestock and poultry | |
| CN103933087A (en) | Method for treating Escherichia coli infection diseases by using creat and amikacin | |
| CN103948657A (en) | Creat/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl | |
| CN103933088A (en) | Method for treating Escherichia coli infection diseases by using creat and antibacterial agents | |
| CN103948912A (en) | Red paeonia/colimycin-containing compound medicine for livestock and fowl | |
| CN104840502A (en) | Composition containing epimedium herb and mequindox and used for livestock and poultry, and preparation method thereof | |
| CN104162145A (en) | Acalypha australis L. and colistin-containing compound medicine for livestock and poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170111 |
|
| RJ01 | Rejection of invention patent application after publication |